The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Corvus Pharmaceuticals, Inc. Common 221015100   17,524,546 3,275,616 SH   SOLE   3,275,616 0 0
Mineralys Therapeutics, Inc. Common 603170101   13,907,924 1,129,807 SH   SOLE   1,129,807 0 0
Palvella Therapeutics, Inc. Common 697947109   4,915,992 409,666 SH   SOLE   409,666 0 0
Paymentus Holdings, Inc. Common- Class A 70439P108   8,952,854 274,039 SH   OTR   274,039 0 0
Rimini Street, Inc. Common 76674Q107   62,919,706 23,565,433 SH   SOLE   23,565,433 0 0
Vacasa, Inc. Common- Class A 91854V107   4,597,283 938,221 SH   SOLE   938,221 0 0